Xilio Therapeutics Appoints Stacey Davis as Chief Business Officer
May 17 2022 - 7:30AM
Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company
developing tumor-selective immuno-oncology therapies for people
living with cancer, today announced that Stacey Davis has been
appointed as chief business officer to further the company’s
corporate and business development strategy that will be central to
its next stage of growth.
“As an accomplished life science leader, Stacey brings
significant strategic business experience building successful
portfolios in oncology and immunology with an in-depth knowledge of
the real-world patient and physician experience,” said René Russo,
Pharm.D., president and chief executive officer of Xilio. “Her
broad operational and business development experience coupled with
her proven track record of leading organizations through critical
development and corporate milestones, will be invaluable as we
advance our pipeline and prepare for preliminary clinical data
readouts anticipated later this year.”
“Xilio has made impressive progress in a short amount of time,
leveraging its geographically precise solutions (GPS) platform to
advance two novel tumor-selective immunotherapies into the clinic
with another IND submission planned for the second half of this
year,” said Ms. Davis. “I look forward to being part of the
company’s evolution as we develop a diverse pipeline of
transformative therapies that aim to significantly improve outcomes
for people living with cancer.”
Ms. Davis brings 25 years of experience in entrepreneurial roles
building teams and leading corporate and portfolio strategy. She
joins Xilio from Novartis Oncology (Novartis), and most recently
served as vice president, lung and immuno-oncology franchise, U.S.
Oncology. In this role, she led the launch of TABRECTA®
(capmatinib) in advanced, non-small cell lung cancer and was
responsible for building out Novartis’ lung cancer franchise,
including broadening the targeted therapies portfolio, in-licensing
and launch preparation for tislelizumab, an anti PD-1, and launch
preparation for canakinumab, a novel anti-IL-1B. Prior to Novartis,
Ms. Davis served as senior vice president and general manager at
Prominex, Inc., a start-up incubated through Roka Biosciences by
NEA, Orbimed and TPG. Ms. Davis also held roles of increasing
responsibility throughout a decade at Johnson & Johnson
(J&J), including serving as U.S. immunology, head, commercial
strategy, insights and operations at Jansen Biotech, Inc., where
she was a senior member of the U.S. leadership team and achieved
above-market growth for a portfolio of products across multiple
indications. Earlier in her tenure at J&J, Ms. Davis founded a
new diagnostics unit as part of Ortho Clinical Diagnostics and also
served in investment and strategy roles with Johnson & Johnson
Development Corporation (JJDC). Earlier in her career, Ms. Davis
held several roles in the financial industry, including at The
Carson Group/Thomson Financial and Merrill Lynch & Co. Ms.
Davis received a B.S.E. in biomedical engineering from Duke
University.
About Xilio Therapeutics
Xilio Therapeutics is a clinical-stage biotechnology company
focused on harnessing the immune system to achieve deep and durable
clinical responses to improve the lives of patients with cancer.
The company is using its proprietary geographically precise
solutions (GPS) platform to rapidly engineer novel molecules,
including cytokines and other biologics, that are designed to
optimize their therapeutic index. These molecules are designed to
localize activity within the tumor microenvironment without
systemic effect, resulting in the potential to achieve enhanced
anti-tumor activity. Xilio is building a pipeline of wholly owned,
tumor-selective, GPS-enabled cytokine and checkpoint inhibitor
product candidates, including its clinical-stage programs, XTX101,
a tumor-selective anti-CTLA-4 monoclonal antibody, and XTX202, a
tumor-selective IL-2, as well as its earlier pipeline, including
XTX301, a tumor-selective IL-12. For more information, please visit
www.xiliotx.com and follow us on Twitter (@xiliotx) and LinkedIn
(Xilio Therapeutics, Inc.).
Cautionary Note Regarding Forward-Looking
Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, including, without limitation, statements
regarding plans and timing related to reporting preliminary Phase 1
clinical data for XTX101 and XTX202 and the submission of an IND
for XTX301; the potential benefits of any of Xilio’s current or
future product candidates in treating patients; and Xilio’s
strategy, goals and anticipated financial performance, milestones,
business plans and focus. The words “aim,” “may,” “will,” “could,”
“would,” “should,” “expect,” “plan,” “anticipate,” “intend,”
“believe,” “estimate,” “predict,” “project,” “potential,”
“continue,” “target” and similar expressions are intended to
identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Any
forward-looking statements in this press release are based on
management’s current expectations and beliefs and are subject to a
number of important risks, uncertainties and other factors that may
cause actual events or results to differ materially from those
expressed or implied by any forward-looking statements contained in
this press release, including, without limitation, risks and
uncertainties related to ongoing and planned research and
development activities, including initiating, conducting or
completing preclinical studies and clinical trials and the timing
and results of such preclinical studies or clinical trials; the
delay of any current or planned preclinical studies or clinical
trials or the development of Xilio’s current or future product
candidates; Xilio’s ability to obtain and maintain sufficient
preclinical and clinical supply of current or future product
candidates; Xilio’s advancement of multiple early-stage programs;
Xilio’s ability to successfully demonstrate the safety and efficacy
of its product candidates and gain approval of its product
candidates on a timely basis, if at all; results from preclinical
studies or clinical trials for Xilio’s product candidates, which
may not support further development of such product candidates;
actions of regulatory agencies, which may affect the initiation,
timing and progress of current or future clinical trials; Xilio’s
ability to obtain, maintain and enforce patent and other
intellectual property protection for current or future product
candidates; Xilio’s ability to obtain and maintain sufficient cash
resources to fund current or future operating expenses and capital
expenditure requirements; the impact of international trade
policies on Xilio’s business, including U.S. and China trade
policies; and the impact of the COVID-19 pandemic on Xilio’s
business, operations, strategy, goals and anticipated milestones.
These and other risks and uncertainties are described in greater
detail in the sections entitled “Risk Factor Summary” and “Risk
Factors” in Xilio’s filings with the U.S. Securities and Exchange
Commission (SEC), including Xilio’s most recent Annual Report on
Form 10-K and any other filings that Xilio has made or may make
with the SEC in the future. Any forward-looking statements
contained in this press release represent Xilio’s views only as of
the date hereof and should not be relied upon as representing its
views as of any subsequent date. Except as required by law, Xilio
explicitly disclaims any obligation to update any forward-looking
statements.
This press release contains hyperlinks to information that is
not deemed to be incorporated by reference in this press
release.
For Investor Inquiries:Sal GiovineChief
Financial Officerinvestors@xiliotx.com
For Media Inquiries: Julissa VianaVice
President, Corporate Communicationsmedia@xiliotx.com
Xilio Therapeutics (NASDAQ:XLO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Xilio Therapeutics (NASDAQ:XLO)
Historical Stock Chart
From Apr 2023 to Apr 2024